Immtech Pharmaceuticals, Inc

Quick facts

Phase 2 pipeline

• DB289
  DB289 is a prodrug that is converted to an active diamidine compound which interferes with DNA binding in parasitic organisms.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Immtech Pharmaceuticals, Inc portfolio CI brief
• Immtech Pharmaceuticals, Inc pipeline updates RSS

Related

• Sector hub: All tracked pharma companies